GE Healthcare, a division of the General Electric Company has begun a clinical study of a new chemical for use in positron emission tomography (PET) imaging that could be used to monitor angiogenesis, the formation of new blood vessels in tumours.
Medical Technology Business Europe (http://mtbeurope.info/news/2006/606014.htm)
